Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The calculation procedure can be found in Additional file 1: Fig S2
Patients may start to see results when their initial dose increases a few weeks after the start of their treatment plan, though results will vary
However, clinical evidence supporting AOD9604 efficacy remains limited compared to the robust Phase 3 data behind tesamorelin, and regulatory approval for AOD9604 in any therapeutic context has not been granted
Oral: SMD, 0.02
License Number 1261 For more information, go to www.novonordisk-us.com or call 1-800-727-6500
US$ 22.95
US$ 29.17
US$ 23.28
US$ 28.47
US$ 23.64
US$ 23.74
US$ 25.82
US$ 29.51
US$ 20.37
US$ 28.90
